The selective ERβ agonist LY500307 has been reported to suppress metastasis of TNBC by inducing tumor cell expression and secretion of IL-1β, resulting in subsequent recruitment of neutrophils to the metastatic site [112]. The gene discussed is ESR2; the disease is neoplasm.